Seminari de Recerca "The ERK5/NF- B signaling pathway targets endometrial cancer proliferation and survival"

  Sala d’actes de la planta baixa de l'edifici Collserola del VHIR — See in map
30/11/2022 -- From 12:00h to 13:00h
Organize :
Institut de Recerca Vall d'Hebron (VHIR)
Modality: Presencial
Share it:

Dra. Nora Diéguez Martínez, Protein kinases and cancer research group (VHIR)

Endometrial cancer (EC) is the most common type of gynaecological cancer in women of developed countries. Despite surgery combined with chemo-/radiotherapy regimens, overall survival of patients with high-risk EC tumors is poor, indicating a need for novel therapies. The MEK5-ERK5 pathway is activated in response to growth factors and to different stressors, including oxidative stress and cytokines. Previous evidence supports a role for the MEK5-ERK5 pathway in the pathology of several cancers. We investigated the role of ERK5 in EC. In silico analysis of the PanCancer Atlas dataset showed alterations in components of the MEK5-ERK5 pathway in 48% of EC patients. Here, we show that ERK5 inhibition or silencing decreased EGF-induced EC cell proliferation, and that genetic deletion of MEK5 resulted in EC impaired proliferation and reduced tumor growth capacity in nude mice. Pharmacologic inhibition or ERK5 silencing impaired NF-kB pathway in EC cells and xenografts. Furthermore, we found a positive correlation between ERK5 and p65/RELA protein levels in human EC tumor samples. Mechanistically, genetic or pharmacologic impairment of ERK5 resulted in downregulation of NEMO/IKKg expression, leading to impaired p65/RELA activity and to apoptosis in EC cells and xenografts, which was rescued by NEMO/IKKg overexpression. Notably, ERK5 inhibition, MEK5 deletion or NF-kB inhibition sensitized EC cells to standard EC chemotherapy (paclitaxel/carboplatin) toxicity, whereas ERK5 inhibition synergized with paclitaxel to reduce tumor xenograft growth in mice. Together, our results suggest that the ERK5-NEMO-NF-kB pathway mediates EC cell proliferation and survival. We propose the ERK5/NF-kB axis as new target for EC treatment.

Host: Dr. José Miguel Lizcano de Vega, Protein kinases and cancer research group (VHIR)

Related activities

IV Split Liver Transplantation Course: Theoretical and Practical Aspects

03/06/2024 - 09:00
More information

Actualización en el diagnóstico y tratamiento de las enfermedades digestivas

03/07/2024 - 09:00
More information

Preceptorship Hiperoxal·luria primària

Hospital Vall d’Hebron. Edifici General (entrada principal) Planta Baixa Sala 6 de Subdirecció. Pg Vall d'Hebron 119-129. Barcelona
03/14/2024 - 09:00
More information

V360 Simulación en Cirugía Vascular versión 3.0

03/27/2024 - 17:00
Especialistas de Angiología y Cirugía Vascular y residentes en formación con el siguiente perfil: • Médicos en formación en Angiología y Cirugía Vascular de 5º año • Especialista de Angiología y Cirugía Vascular de menos de 10 años de experiencia
More information

Subscribe to our newsletters and be a part of Campus Life

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.